



ROLE OF HYDROCORTISONE EITHER ALONE OR COMBINED WITH FLUDROCORTISONES IN THE OUTCOME OF SEPTIC SHOCK IN ADULTS –A STUDY IN SOUTH INDIA

Machanuru Subba Reddy¹, Lohith Kumar^{2*}

¹Assistant Professor of Anaesthesia, Viswabharathi Medical College and General Hospital, Kurnool, A.P,India.

²Assistant Professor of Anaesthesia, Madha Medical college and Hospital, Chennai, India.

ABSTRACT

Septic shock is distinguished by a dysregulated host response to infection. It may resulting in life-threatening circulatory, cellular, and metabolic abnormalities. The short term mortality is approximately 45 to 50%, and survivors of sepsis may have subsequent long-term cognitive decline. At a distance from early hemodynamic and respiratory resuscitation and appropriate anti infective treatments, there is no approved adjunct therapy for sepsis. In this study we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs and their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. At day 90, death had occurred in 264 of 620 patients (42.5%; 95% confidence interval [CI], 39.0 to 45.0) in the hydrocortisone-plus-fludrocortisone group and in 308 of 610 patients (50.4%; 95% CI, 46.1 to 55.1) in the placebo group ($P = 0.03$) (Table 2 and Fig. 1). The relative risk of death was 0.99 (95% CI, 0.78 to 0.99) in favor of hydrocortisone-plus-fludrocortisone therapy. In this trial involving patients with septic shock. Seven -day treatment with a 50-mg intravenous bolus of hydrocortisone every 6 hours and a everyday dose of 50 µg of oral fludrocortisone ended in decrease mortality at day 90 and at ICU and clinic discharge than placebo among adults with septic shock.

Keywords: - Mortality, septic shock, hydrocortisone shock reversal, fludrocortisone

Access this article online		
Home page: www.mcmed.us/journal/abs	Quick Response code	
Received:14.03.2019	Revised:10.04.2019	Accepted:27.04.2019

INTRODUCTION

Septic shock is distinguished by a dysregulated host response to infection. It may resulting in life-threatening circulatory, cellular, and metabolic abnormalities. [1] The short term mortality is approximately 45 to 50%, and survivors of sepsis may have subsequent long-term cognitive decline. At a distance from early hemodynamic and respiratory resuscitation and appropriate anti infective treatments, there is no approved adjunct therapy for sepsis. The

Surviving Sepsis Campaign recommends that, in the first hour of sepsis recognition, physicians obtain blood cultures, administer broad-spectrum antibiotics, start appropriate fluid resuscitation and begin vasopressors whenever needed. Beyond these core measures, there has been little change in the management of sepsis.

Corticosteroids were the anti inflammatory drug of sepsis. It is related with a dysregulated response of the hypothalamic–pituitary–adrenal axis that may involve

Corresponding Author: **Dr. Lohith Kumar** Email: drvrvkk@gmail.com

any of the steps from cortisol production to cortisol use by cells. [2] Although corticosteroids have been shown to improve blood pressure there are conflicting results on survival benefits in recent large randomized controlled trials (RCTs) and systematic reviews, resulting in the lack of definitive recommendations in several clinical guidelines. [3] Between the different corticosteroid treatments, there was a dual treatment with hydrocortisone and fludrocortisone for septic shock results. Hydrocortisone act as both glucocorticoid and mineralocorticoid activities; whereas fludrocortisone, a synthetic corticosteroid, possesses very potent mineralocorticoid activity. [4] Hydrocortisone has been extensively examined in sepsis, and fludrocortisone has been used for patients with aldosterone deficiency. Dual therapy using these two medications is recommended for some patients with primary adrenal insufficiency. Considering that patients with septic shock have been found to have unexpectedly low aldosterone levels due to hypothalamic–pituitary–adrenal axis abnormalities, dual treatment with hydrocortisone and fludrocortisone should be further validated as a type of corticosteroid treatment for septic shock [5].

As a result, we understood a systematic review and meta analysis to identify beneficial effects of the dual treatment with hydrocortisone and fludrocortisone for patients with septic shock, the aim of the present study Evaluation of the role of hydrocortisone either alone or combined with fludrocortisones in the outcome of septic shock in adults.

MATERIAL AND METHODS

Information on the design and conduct of the activated protein C and Corticosteroids for Human.

- Otherwise, deferred written informed consent was obtained from patients.
- Participants or their legally authorized next of kin provided written informed consent before inclusion whenever possible.
- Otherwise, deferred written informed consent was obtained from patients.

The exclusion criteria have been detailed elsewhere. Major exclusion criteria were the presence of septic shock for at least 24 hours, a high risk of bleeding pregnancy or lactation, underlying conditions that could affect short-term survival, known hypersensitivity to drotrecogin alfa (activated), or previous treatment with corticosteroids. After the withdrawal of Xigris from the market, the exclusion criteria that were relevant only to drotrecogin alfa (activated) were removed [6].

Patients in intensive care units (ICUs) were eligible for inclusion in the trial if they had indisputable or probable septic shock¹⁵ for less than 24 hours. Septic shock was defined as the presence of a clinically or

microbiologically documented infection, a Sequential Organ Failure Assessment (SOFA)¹⁶ score of 3 or 4 (on a scale of 0 to 4 for each of six organ systems, with higher scores indicating more severe organ dysfunction) for at least two organs and at least 6 hours, and receipt of vasopressor therapy (norepinephrine, epinephrine, or any other vasopressor at a dose of ≥ 0.25 μ g per kilogram of body weight per minute or ≥ 1 mg per hour) for at least 6 hours to maintain a systolic blood pressure of at least 90 mm Hg /a mean blood pressure of at least 65 mm Hg.

Randomization and Trial Agents:

Patients were randomly assigned in permuted blocks of eight to receive hydrocortisone-plus fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos ((mannitol [133.6 mg], disodium phosphate [8.73 mg], and sodium phosphate [0.92 mg])). Hydrocortisone was administered as a 50-mg intravenous bolus every 6 hours, and fludrocortisone was given as a 50- μ g tablet through a nasogastric tube once daily in the morning. Trial agents were administered for 7 days without tapering.

Randomization, plasma total cortisol levels were measured before, 30 and 60 minutes after, an intravenous bolus of 250 μ g of corticotrophin (Synacthen). The variables that were investigated at baseline and during the 180-day follow-up have been detailed elsewhere. Non experimental interventions were harmonized across centers according to the 2008 Surviving Sepsis Campaign guidelines, including anti infective treatments, hemodynamic and respiratory management, and blood glucose control.

Investigators followed national guidelines for the prevention of super infection. Neuromuscular blocking agents were discouraged except in the first 24 hours in the presence of refractory hypoxemia. Investigators' adherence to guidelines was checked at each investigators' meeting.

Statistical Analysis Of Prsent Study We anticipated a 90-day mortality of 45% among patients with septic shock.¹⁹ According to the 2-by-2 factorial design with a two-sided formulation, 320 patients were needed in each group (i.e., a total of 1280 patients) to detect an absolute difference of 10 percentage points in 90-day mortality ($\alpha = 0.05$ and power at 95%) between either drotrecogin alfa and placebo.

An intention-to-treat analysis was planned to be performed after all the participants had completed the 180-day follow-up and according to the 2-by-2 factorial design. Owing to the withdrawal of Xigris from the market in 2011, the trial continued with two parallel groups (see the protocol) and was underpowered to assess the effect of drotrecogin alfa (activated). The sponsor terminated the trial when the expiration dates of the trial

agents were reached and 1241 patients (97% of the expected sample size) had been enrolled.

The analysis compared all the patients assigned to receive hydrocortisone plus fludrocortisone with those assigned to receive corresponding placebos. Continuous variables are presented as means and standard deviations. Categorical variables are presented as the number of patients in each category and the corresponding percentages. Missing data were not replaced. The effects of trial agents on the frequency of fatal events (mortality at day 28, at day 90, at discharge from the ICU or hospital, and at day 180) and safety outcomes were compared with the use of logistic regression models and the chi-square test. Continuous variables were compared with the use of analyses of variance and t-tests. Cumulative event curves (censored end points) were estimated with the Kaplan–Meier procedure, and Cox models and the log-rank test were used to compare the effects of trial agents (time to ICU and hospital discharge).

The Fine and Gray sub distribution hazard regression models, which extend the Cox model to competing risk data by considering the hazard function associated with the cumulative incidence function, were used to compare the effects of trial agents (time to weaning from vasopressors, to weaning from mechanical ventilation, and to reaching a SOFA score <6). No adjustment for multiple testing was made. All analyses were conducted with SAS statistical software, version 9.4.

RESULTS

There were 4 participating centers the first and last patients were recruited on September 2, 2021 and September 23, 2022, respectively to check the quality of the trial agents and the distribution of serious adverse events.

On October 1, 2021, the data and safety monitoring board confirmed the conformity of the trial to the marketing- authorization application for fludrocortisone and hydrocortisone and the quality of their placebos; the board also confirmed that the distribution of serious adverse events between the groups did not justify halting the trial. The trial was completed on December 23, 2021

Patient demographic information, severity-of-illness scores, characteristics of infection, and remedies at baseline had been similar inside the two organizations. Most patients have been admitted from a scientific ward and had extreme septic shock, as evidenced by high Simplified Acute Physiology Score II (SAPS II) values (range, 0 to 163, with better rankings indicating extra severity of illness), high lactate levels, and an excessive degree of vasopressor dependency (imply dose of

norepinephrine, 1 µg in keeping with kilogram in keeping with minute).

Most patients had community-acquired infection, and the lung became the maximum common site of infection. The preliminary antimicrobial treatment became judged adequate in ninety seven percentage of the sufferers who obtained placebo and 97.9% of folks that received corticosteroids

Primary outcome

At day 90, death had occurred in 264 of 620 patients (42.5%; 95% confidence interval [CI], 39.0 to 45.0) in the hydrocortisone-plus-fludrocortisone group and in 308 of 610 patients (50.4%; 95% CI, 46.1 to 55.1) in the placebo group ($P = 0.03$) (Table 2 and Fig. 1). The relative risk of death was 0.99 (95% CI, 0.78 to 0.99) in favor of hydrocortisone-plus-fludrocortisone therapy.

Secondary outcomes

Mortality was significantly lower in the hydrocortisone- plus-fludrocortisone group than in the placebo group at ICU discharge (35% [215 of 613 patients] vs. 42.6% [265 of 625 patients], $P = 0.04$), hospital discharge (37% [229 of 613 patients] vs. 45% [282 of 625 patients], $P = 0.02$), and day 180 (46.7% [285 of 610 patients] vs. 52.6% [328 of 623 patients], $P = 0.04$). Patients in the hydrocortisone-plus-fludrocortisone group had a significantly shorter time than those in the placebo group to weaning from mechanical ventilation ($P = 0.006$), to weaning from vasopressor therapy ($P < 0.001$), and to reaching a SOFA score below 6 ($P < 0.001$). Similarly, patients in the hydrocortisone-plus-fludrocortisone group had significantly more vasopressor-free days to day 28 than those in the placebo group ($P < 0.001$) and significantly more organ-failure-free days to day 28 ($P = 0.003$).

Risk of bias and summary of findings

A total of 324 of 612 patients (52.9%) in the hydrocortisone-plus-fludrocortisone group and 353 of 616 patients (57.3%) in the placebo group had at least one serious adverse event by day 180 ($P = 0.05$) (Table 3). The risk of gastroduodenal bleeding was not significantly higher with hydrocortisone plus fludrocortisone than with placebo (relative risk, 0.77; 95% CI, 0.56 to 1.34; $P = 0.55$), nor was the risk of superinfection (relative risk, 1.07; 95% CI, 0.91 to 1.30; $P = 0.30$). However, the risk of hyperglycemia was significantly higher with hydrocortisone plus fludrocortisone (relative risk, 1.07; 95% CI, 1.03 to 1.13; $P = 0.002$).

DISCUSSION

In present trial regarding adults with septic shock, all-purpose mortality changed into decrease with

hydrocortisone plus fludrocortisone than with placebo at day 90, at discharge from the ICU and clinic, and at day one hundred eighty. The time to weaning from vasopressors, to weaning from mechanical ventilation, and to reaching a SOFA score beneath 6 turned into shorter with hydrocortisone plus fludrocortisone than with placebo. The wide variety of days alive and freed from vasopressors and organ failure turned into better with hydrocortisone plus fludrocortisone than with placebo.

The chance of secondary infections, gastroduodenal bleeding, or neurologic sequelae become no longer considerably better with hydrocortisone plus fludrocortisone than with placebo, however the danger of hyperglycemia turned into significantly higher with hydrocortisone plus fludrocortisone. There turned into a few imbalance between the two groups inside the distribution of pathogens, with barely extra viral infections inside the hydrocortisone-plus-fludrocortisone institution than in the placebo group.

The mechanisms by way of which corticosteroids may favorably affect the final results of sufferers with septic shocks were specific recently. [7] In brief, corticosteroids improve cardiovascular feature with the aid of restoring effective blood volume via multiplied mineralocorticoid pastime and by using growing systemic vascular resistance, an effect this is partly related to endothelial glucocorticoid receptors.[8] This may provide an explanation for why in our trial there was much less want for vasopressors with hydrocortisone plus fludrocortisone than with placebo. Corticosteroids attenuate inflammation in various organs in both animals and humans with sepsis, an effect in part associated with inhibition of nuclear factor κ B (NF- κ B).[9] In our trial, hydrocortisoneplus- fludrocortisone therapy increased the decision of organ failure in adults with septic shock.

With appreciate to ninety-day all-reason mortality, there was an absolute difference of 6 percent points and a relative distinction of 12% that desired hydrocortisone plus fludrocortisone over placebo; those findings are in keeping with those of a current Cochrane assessment. In this systematic evaluate, only 2 of 33 trials have been powered to address the results of a long (≥ 5 days) direction of low-dose corticosteroids on mortality. [10] The first trial (Ger-Inf-05), wherein patients obtained hydrocortisone plus fludrocortisone or matching placebos for 7 days, confirmed an absolute difference of 6 percent factors in 28-day mortality in choose of hydrocortisone plus fludrocortisone.

The second trial (Corticosteroid Therapy of Septic Shock [CORTICUS]) showed no significant survival advantage from an eleven-day route of hydrocortisone by myself. In a more latest trial concerning 380 adults with intense sepsis (Hydrocortisone for Prevention of Septic Shock

[HYPRESS]), hydrocortisone alone failed to save you septic shock. That trial turned into not powered to deal with the outcomes of hydrocortisone on mortality and excluded sufferers with shock.

Here are principal variations among trials that confirmed a survival benefit from corticosteroid remedy (APROCCHSS and Ger-Inf-05) and people that did now not (CORTICUS and HYPRESS). First, in the APROCCHSS and Ger-Inf-05 trials, fludrocortisone changed into delivered to hydrocortisone to provide extra mineralocorticoid potency. It changed into administered enterally inside the absence of an intravenous formula of this drug.

The intent for including mineralocorticoid treatment is that an experimental sepsis has a look at showed marked NF- κ B-mediated down-regulation of vascular mineralocorticoid receptors. 23 Treatment with aldosterone, a mineralocorticoid-receptor agonist, restored α 1-adrenoceptor expression, improved contractile reaction to phenylephrine, and improved survival in mice with endotoxic shock. In a latest pharmacokinetic take a look at involving adults with septic surprise, enteral management of fifty μ g of fludrocortisone resulted in plasma concentrations of the drug that exerted great mineralocorticoid consequences, with some interindividual variability. [11]

Second, the APROCCHSS and Ger-Inf-05 trials focused on sufferers with septic surprise whose condition did not beautify after initial resuscitation in keeping with the 6-hour package deal of care mentioned in the Surviving Sepsis Campaign guidelines. For the ones patients, norepinephrine at a dose of more than 0.25 μ g consistent with kilogram in step with minute for more than 6 hours turned into required in order for hemodynamic stabilization to be finished. This corporation of sufferers changed into decided on because they will be at high danger for loss of life, which makes them the pleasant goal group for adjunct treatment.

The crude in-health center mortality Of fifty four percentage that was determined within the placebo institution of the APROCCHSS trial is near that suggested thru the Sepsis-three challenge pressure. 2,3 Patients in the APROCCHSS trial have been sicker than the ones inside the CORTICUS trial, as evidenced thru higher SOFA ratings and higher SAPS II values (and were more likely to be admitted from scientific wards.

Hence, the Ger-Inf-05 and APROCCHSS trials independently showed a survival benefit with hydrocortisone plus fludrocortisone in adults with septic shock and continual vasopressor dependency and organ failures.

CONCLUSION

Seventh-day treatment with a 50-mg intravenous bolus of hydrocortisone every 6 hours and a everyday

dose of fifty µg of oral fludrocortisone ended in decrease mortality at day 90 and at ICU and clinic discharge than

placebo among adults with septic shock.

REFERENCES

1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; 315: 801-10.
2. Annane D. The role of ACTH and corticosteroids for sepsis and septic shock:an update *Front Endocrinol (Lausanne)*2016; 7: 70.
3. Keh D, Trips E, Marx G, et al. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. *JAMA* 2016; 316:1775–85.
4. Hamitouche N, Comets E, Ribot M, Alvarez JC, Bellissant E, Laviolle B. Population pharmacokinetic-pharmacodynamic model of oral fludrocortisone and intravenous hydrocortisone in healthy volunteers. *AAPS J.* 2017; 19: 727–35.
5. Moraes RB, Friedman G, Viana MV, Tonietto T, Saltz H, Czepielewski MA. Aldosterone secretion in patients with septic shock: a prospective study. *Arq Bras Endocrinol. Metab.*2013; 57: 636–41.
6. Annane D, Buisson CB, Cariou A, et al. Design and conduct of the Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial. *Ann Intensive Care* 2016; 6: 43.
7. Annane D. The role of ACTH and corticosteroids for sepsis and septic shock: an update. *Front Endocrinol (Lausanne)* 2016; 7: 70.
8. Goodwin JE, Feng Y, Velazquez H, Sessa WC. Endothelial glucocorticoid receptor is required for protection against sepsis. *Proc Natl Acad Sci U S A* 2013; 110:306-11.
9. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP. Nuclear factor- κ B- and glucocorticoid receptor mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome: evidence for inflammation-induced target tissue resistance to glucocorticoids. *Neuroimmunomodulation* 2005;12: 321-38.
10. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. *N Engl J Med* 2008; 358: 111-24.
11. Polito A, Hamitouche N, Ribot M, et al. Pharmacokinetics of oral fludrocortisone in septic shock. *Br J Clin Pharmacol* 2016; 82: 1509-16.

Cite this article:

Machanuru Subba Reddy, Lohith Kumar. Role of hydrocortisone either alone or combined with fludrocortisone in the outcome of septic shock in adults –A study in South India. *Acta Biomedica Scientia*, 2019, 6(3), 208-212.



Attribution-NonCommercial-NoDerivatives 4.0 International